Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mining bacterial genomes for antimicrobial targets.

H Loferer1

  • 1GPC Biotech AG, Fraunhoferstrasse 20, D-82152 Martinsried/Munich, Germany. Hannes.Loferer@gpc-biotech.com

Molecular Medicine Today
|December 2, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

Leukemia·2013
Same author

EcfE, a new essential inner membrane protease: its role in the regulation of heat shock response in Escherichia coli.

The EMBO journal·2001
Same author

DNA microarray technology and antimicrobial drug discovery.

Pharmacogenomics·2001
Same author

A genome-based approach for the identification of essential bacterial genes.

Nature biotechnology·1998
Same author

Availability of the fibre subunit CsgA and the nucleator protein CsgB during assembly of fibronectin-binding curli is limited by the intracellular concentration of the novel lipoprotein CsgG.

Molecular microbiology·1998
Same author

Replacement of Pro109 by His in TlpA, a thioredoxin-like protein from Bradyrhizobium japonicum, alters its redox properties but not its in vivo functions.

FEBS letters·1997

Genomic sequencing revolutionizes antimicrobial drug discovery. Microbial genomics, bioinformatics, and new technologies offer diverse targets for novel medicine development.

Area of Science:

  • Genomics
  • Bioinformatics
  • Drug Discovery

Background:

  • Whole-genome sequencing is transforming medicine development.
  • Over 30 microbial genomes are available, offering vast genetic information.
  • Antimicrobial drug discovery can leverage this genomic diversity.

Purpose of the Study:

  • To review how microbial genomics has reshaped antimicrobial drug discovery strategies.
  • To highlight the application of bioinformatics and genomics-based technologies.

Main Methods:

  • Bioinformatics analysis of microbial genomes.
  • Application of novel genetic approaches.
  • Genomics-based technologies, including DNA microarrays for gene expression analysis.

Main Results:

Related Experiment Videos

  • Genomic information provides a rich resource for identifying new drug targets.
  • Bioinformatics tools enable efficient analysis of large genomic datasets.
  • Integration of genomics and experimental approaches accelerates the discovery pipeline.

Conclusions:

  • Microbial genomics has fundamentally changed antimicrobial drug discovery paradigms.
  • Leveraging genomic data and advanced technologies is crucial for developing new medicines.
  • The future of antimicrobial drug discovery is intrinsically linked to genomic insights.